Utility of presepsin (sCD14-ST) as a diagnostic and prognostic marker of sepsis in the emergency department

Clinica Chimica Acta

Volumn 450, Issue , 2015, Pages 169-175

  Carpio, Ricardo ^a,b   Zapata, Juan ^a   Spanuth, Eberhard ^c   Hess, Georg ^d  

^a HOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS   (Peru)

^b UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

^c DIAneering Diagnostics Engineering and Research   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Diagnosis; Emergency department; Outcome prediction; Presepsin; Prognosis; Sepsis

Indexed keywords

BIOLOGICAL MARKER; CD14 ANTIGEN; PRESEPSIN; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT; PRESEPSIN PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; EMERGENCY WARD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; ADOLESCENT; BLOOD; DIFFERENTIAL DIAGNOSIS; EMERGENCY HEALTH SERVICE; MIDDLE AGED; SHOCK, SEPTIC; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD14; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SEPSIS; SHOCK, SEPTIC; YOUNG ADULT;

EID: 84940094819     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.08.013     Document Type: Article

References (24)

1. Wang H.E., Shapiro N.I., Angus D.C., Yealy D.M. National estimates of severe sepsis in United States emergency departments. Crit. Care Med. 2007, 35:1928-1936.
2. Wilhelm J., Hettwer S., Hammer D., Schürmann M., Christoph A., Amoury M., et al. Outcome prediction using clinical scores and biomarkers in patients with presumed infection in the emergency department. Med. Klin. Intensivmed. Notfmed. 2012, 107:558-563.
3. Ferrer R., Martin-Loeches I., Phillips G., Osborn T.M., Townsend S., Dellinger R.P., et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit. Care Med. 2014, 42:1749-1755.
4. Ruiz-Alvarez M.J., Garcia-Valdecasa S., De Pablo R., Sanchez Gracia M., Coca C., Groenewald T.W., et al. Diagnostic efficacy and prognostic value of serum procalcitonin concentration in patients with suspected sepsis. J. Intensive Care Med. 2009, 24:63-71.
5. Yaegashi Y., Shirakawa K., Sato N., Suzuki Y., Kojika M., Imai S., et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J. Infect. Chemother. 2005, 11:234-238.
6. Endo S., Suzuki J., Takahashi G., Shozushima I., Ishikura H., Murai A., et al. Usefulness of PSEP in the diagnosis of sepsis in a multicenter prospective study. J. Infect. Chemother. 2012, 18:891-897.
7. Ulla M., Pizzolato E., Lucchiari M., Loiacono M., Soardo F., Forno D., et al. Diagnostic and prognostic value of PSEP in the management of sepsis in the emergency department: a multicentre prospective study. Crit. Care 2013, 17. R168.
8. Liu B., Chen Y.-X., Yin Q., Zhao Y.-Z., Li C.-S. Diagnostic value and prognostic evaluation of PSEP for sepsis in an emergency department. Crit. Care 2013, 17. R244. 10.1186/cc13070.
9. Romualdo L.G.G., Torella P.E., Gonzalez M.V., Sanchez R.J., Holgado A.H., Freire A.O., et al. Diagnostic accuracy of PSEP (soluble CD14 subtype) for prediction of bacteremia in patients with systemic inflammatory response syndrome in the Emergency Department. Clin. Biochem. 2014, 47:505-508.
10. Masson S., Caironi P., Spanuth E., Thomae R., Panigada M., Sangiorgi G., et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit. Care 2014, 18:R6.
11. American College of Chest Physicians, Society of Critical Care Medicine Consensus Conference Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med. 1992, 20:864-874.
12. Kurihara T., Yanagida A., Yokoi H., Koyota A., Matsuya T., Ogawa J., et al. Evaluation of cardiac assays on a benchtop chemiluminescent enzyme immunoassay analyzer, PATHFAST. Anal. Biochem. 2008, 375:144-146.
13. Levy M.M., Dellinger R.P., Townsend S.R., Linde-Zwirble W.T., Marshall J.C., Bion J., et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010, 36:222-231.
14. Dellinger R.P., Levy M.M., Rhodes A., Anane D., Gerlach H., Opal S.M., et al. The Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit. Care Med. 2013, 41:580-637.
15. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
16. Majuran M., Clancy M. Determination of the size of the different sepsis categories presenting to a UK teaching hospital emergency department. Emerg. Med. J. 2008, 25(1):11-14.
17. Puskarich M.A., Marchick M.R., Kline J.A., Steuerwald M.T., Jones A.E. One year mortality of patients treated with an emergency department based early goal directed therapy protocol for severe sepsis and septic shock: a before and after study. Crit. Care 2009, 13. R167.
18. Riedel S. Procalcitonin and the role of biomarkers in the diagnosis and management of sepsis. Diagn. Microbiol. Infect. Dis. 2012, 73:221-227.
19. Okamura Y., Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin. Chim. Acta 2011, 412:2157-2161.
20. Vodnik T., Kaljevic G., Tadic T., Majkic-Singh N. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin. Chem. Lab. Med. 2013, 51:2053-2062.
21. Mitsubishi Chemical Europe: Product information PF1201-K 2013 MCM ver 2 2013.01 PATHFAST Presepsin.
22. Spanuth E., Ebelt H., Ivandic B., Werdan K. Diagnostic and prognostic value of presepsin (soluble CD 14 subtype) in emergency patients with early sepsis using the new assay PATHFAST Presepsin. Advances in Clinical Chemistry and Laboratory Medicine. Proceedings of the IFCC WorldLab/EuroMedLab Congress Berlin 2011, Berlin/Boston 2012 2012, 129-133. H. Renz, R. Tauber (Eds.).
23. Vincent J.L., Moreno R., Takala J., Willats S., De Mendonca A., Bruining H., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996, 22:707-710.
24. Kweon O.J., Choi J.-H., Park S.K., Park A.J. Usefulness of presepsin (sCD14 subtype) measurements as a new marker for the diagnosis and prediction of disease severity of sepsis in the Korean population. J. Crit. Care 2014, 29:965-970.